Ampio Pharmaceuticals has begun recruiting and enrolling patients in a Phase I multi-center, randomized, controlled trial for a total of 40 patients that will assess the safety and efficacy of inhaled Ampion added to the standard of care (SOC) for ...
Ampio Pharmaceuticals announces the receipt of an Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA), allowing the Company to proceed with clinical trials for the use of Ampion as an inhalation therapy for respiratory ...
Ampio Pharmaceuticals is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 (COVID-19) induced Acute Respiratory Distress Syndrome (ARDS).